BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Plesa A, Dumontet C, Mattei E, Tagoug I, Hayette S, Sujobert P, Tigaud I, Pages MP, Chelghoum Y, Baracco F, Labussierre H, Ducastelle S, Paubelle E, Nicolini FE, Elhamri M, Campos L, Plesa C, Morisset S, Salles G, Bertrand Y, Michallet M, Thomas X. High frequency of CD34+CD38-/low immature leukemia cells is correlated with unfavorable prognosis in acute myeloid leukemia. World J Stem Cells 2017; 9(12): 227-234 [PMID: 29321824 DOI: 10.4252/wjsc.v9.i12.227]
URL: https://www.wjgnet.com/1948-0210/full/v9/i12/227.htm
Number Citing Articles
1
Jesse M. Tettero, Sylvie Freeman, Veit Buecklein, Adriano Venditti, Luca Maurillo, Wolfgang Kern, Roland B. Walter, Brent L. Wood, Christophe Roumier, Jan Philippé, Barbara Denys, Jeffrey L. Jorgensen, Marie C. Bene, Francis Lacombe, Adriana Plesa, Monica L. Guzman, Agnieszka Wierzbowska, Anna Czyz, Lok Lam Ngai, Adrian Schwarzer, Costa Bachas, Jacqueline Cloos, Marion Subklewe, Michaela Fuering-Buske, Francesco Buccisano. Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyHemaSphere 2022; 6(1): e676 doi: 10.1097/HS9.0000000000000676
2
Yue Sun, Gelan Zhu, Hua Zhong. Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patientsEuropean Journal of Haematology 2024;  doi: 10.1111/ejh.14187
3
Lok Lam Ngai, Angèle Kelder, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos. MRD Tailored Therapy in AML: What We Have Learned So FarFrontiers in Oncology 2021; 10 doi: 10.3389/fonc.2020.603636
4
Jacqueline Cloos, Lok Lam Ngai, Michael Heuser. Understanding differential technologies for detection of MRD and how to incorporate into clinical practiceHematology 2023; 2023(1): 682 doi: 10.1182/hematology.2023000454
5
Adriana Plesa, Christophe Roumier, Joris Gutrin, Marie-Virginie Larcher, Marie Balsat, Octavia Cadassou, Fiorenza Barraco, Gaëlle Fossard, Amandine Baudouin, Hélène Labussière, Isabelle Tigaud, Sophie Ducastelle, Sandrine Hayette, Pierre Sujobert, Maël Heiblig, Mohamed Elhamri, Xavier Thomas. Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometryLeukemia Research 2021; 111: 106673 doi: 10.1016/j.leukres.2021.106673
6
Heejoo Han, Ja Min Byun, Dong-Yeop Shin, Sung-Soo Yoon, Youngil Koh, Junshik Hong, Inho Kim, Chansup Lee, Hyeonjoo Yoo, Hongseok Yun, Man Jin Kim, Sung Im Cho, Moon-Woo Seong, Sung Sup Park. Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemiaThe Korean Journal of Internal Medicine 2021; 36(2): 401 doi: 10.3904/kjim.2020.014
7
Qian Lai, Juan Song, Jie Zha, Huijian Zheng, Manman Deng, Yilong Liu, Wei Lin, Zhi Zhu, Huimin Zhang, Bing Xu, Chaoyong Yang. Microfluidic chip with reversible interface for noninvasive remission status monitoring and prognosis prediction of acute myeloid leukemiaBiosensors and Bioelectronics 2023; 219: 114803 doi: 10.1016/j.bios.2022.114803
8
Lacey Brennan, Aru Narendran. Cancer Stem Cells in the Development of Novel Therapeutics for Refractory Pediatric LeukemiaStem Cells and Development 2019; 28(19): 1277 doi: 10.1089/scd.2019.0035
9
Vincenzo Maria Perriello, Ilaria Gionfriddo, Roberta Rossi, Francesca Milano, Federica Mezzasoma, Andrea Marra, Orietta Spinelli, Alessandro Rambaldi, Ombretta Annibali, Giuseppe Avvisati, Francesco Di Raimondo, Stefano Ascani, Brunangelo Falini, Maria Paola Martelli, Lorenzo Brunetti. CD123 Is Consistently Expressed on NPM1-Mutated AML CellsCancers 2021; 13(3): 496 doi: 10.3390/cancers13030496
10
Sylvia Snauwaert, Farzaneh Rahmani, Bart Vandekerckhove, Tessa Kerre. Cancer Immunology2020; : 103 doi: 10.1007/978-3-030-57949-4_4
11
Atefe Rahmati, Sajad Goudarzi, Maryam Sheikhi, Payam Siyadat, Gordon A Ferns, Hossein Ayatollahi. The Emerging Roles of Aldehyde Dehydrogenase in Acute Myeloid Leukemia and Its Therapeutic PotentialAnti-Cancer Agents in Medicinal Chemistry 2023; 23(3): 246 doi: 10.2174/1871520622666220610154043
12
Shiwen Wu, Wei Zhang, Dongqin Shen, Jianle Lu, Li Zhao. PLCB4 upregulation is associated with unfavorable prognosis in pediatric acute myeloid leukemiaOncology Letters 2019;  doi: 10.3892/ol.2019.10921
13
Weronika Stolpa, Agnieszka Mizia-Malarz, Magdalena Zapała, Bartosz Zwiernik. Can CD34+CD38− lymphoblasts, as likely leukemia stem cells, be a prognostic factor in B-cell precursor acute lymphoblastic leukemia in children?Frontiers in Pediatrics 2023; 11 doi: 10.3389/fped.2023.1213009
14
Jianbiao Zhou, Jing-Yuan Chooi, Ying Qing Ching, Jessie Yiying Quah, Sabrina Hui-Min Toh, Yvonne Ng, Tuan Zea Tan, Wee-Joo Chng. NF-κB promotes the stem-like properties of leukemia cells by activation of LIN28BWorld Journal of Stem Cells 2018; 10(4): 34-42 doi: 10.4252/wjsc.v10.i4.34
15
Diana Hanekamp, Alexander N. Snel, Angèle Kelder, Willemijn J. Scholten, Naeem Khan, Marlen Metzner, Maria Irno‐Consalvo, Mayumi Sugita, Anja de Jong, Sjoerd Oude Alink, Harrie Eidhof, Miriam Wilhelm, Michaela Feuring‐Buske, Jennichjen Slomp, Vincent H. J. van der Velden, Edwin Sonneveld, Monica Guzman, Gail J. Roboz, Francesco Buccisano, Paresh Vyas, Sylvie Freeman, Costa Bachas, Gert J. Ossenkoppele, Gerrit J. Schuurhuis, Jacqueline Cloos. Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre settingBritish Journal of Haematology 2020; 190(6): 891 doi: 10.1111/bjh.16594
16
L.M. Shlapatska, A.S. Polishchuk, D.F. Gluzman. EXPRESSION PROFILE OF SOME MARKERS OF LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIAOncology 2023; 25(3): 180 doi: 10.15407/oncology.2023.03.180
17
Maël Heiblig, Mohamed Elhamri, Xavier Thomas, Adriana Plesa, Emmanuel Raffoux, Sandrine Hayette. A phase 1 study of chemosensitization with plerixafor plus G-CSF in adults with relapsed acute myeloid leukemiaLeukemia Research 2018; 72: 7 doi: 10.1016/j.leukres.2018.07.017
18
Grégoire Le Meur, Adriana Plesa, Marie-Virginie Larcher, Gaëlle Fossard, Fiorenza Barraco, Sandrine Loron, Marie Balsat, Sophie Ducastelle-Leprêtre, Lila Gilis, Xavier Thomas, Hervé Ghesquières, Isabelle Tigaud, Sandrine Hayette, Sarah Huet, Pierre Sujobert, Myriam Renault, Rubio Marie Thérèse, Mauricette Michallet, Hélène Labussière-Wallet, Maël Heiblig. Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric StudyTransplantation and Cellular Therapy 2023; 29(1): 38.e1 doi: 10.1016/j.jtct.2022.09.003
19
Teresa Caballero-Velázquez, Olga Pérez-López, Ana Yeguas Bermejo, Eduardo Rodríguez Arbolí, Enrique Colado Varela, Amparo Sempere Talens, María Belén Vidriales, María Solé-Rodríguez, Covadonga Quirós Caso, Estefanía Pérez López, Marta Reinoso Segura, Concepción Prats-Martín, Pau Montesinos, Jose A. Pérez-Simón. Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter StudyCancers 2023; 15(5): 1609 doi: 10.3390/cancers15051609
20
Caroline Dix, Tsun-Ho Lo, Georgina Clark, Edward Abadir. Measurable Residual Disease in Acute Myeloid Leukemia Using Flow Cytometry: A Review of Where We Are and Where We Are GoingJournal of Clinical Medicine 2020; 9(6): 1714 doi: 10.3390/jcm9061714
21
Etienne Paubelle, Adriana Plesa, Sandrine Hayette, Mohamed Elhamri, Florence Zylbersztejn, Olivier Hermine, Gilles Salles, Xavier Thomas. Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with Overexpression of EVI1Oncology and Therapy 2019; 7(2): 121 doi: 10.1007/s40487-019-0095-9
22
Maura R.V. Ikoma-Colturato, Alef Rafael Severino, Juliana Fernanda dos Santos Tosi, Camila Marques Bertolucci, Yeda Midori Nakamura Cuoco, Ederson Roberto de Mattos, Iago Colturato, Fernanda Barbieri Rodrigues Silva, Mair Pedro de Souza, Anderson João Simione, Vergilio Antonio Rensi Colturato. Clinical validation of a 10-color flow cytometry panel to detect measurable residual disease in acute myeloid leukemiaLeukemia Research 2024; 140: 107482 doi: 10.1016/j.leukres.2024.107482
23
N.N. Mamaev, A.I. Shakirova, E.V. Morozova, T.L. Gindina. EV/1-Positive Leukemias and Myelodysplastic Syndromes: Theoretical and Clinical Aspects (Literature Review)Clinical oncohematology 2021; 14(1): 103 doi: 10.21320/2500-2139-2021-14-1-103-117
24
Michael Heuser, Sylvie D. Freeman, Gert J. Ossenkoppele, Francesco Buccisano, Christopher S. Hourigan, Lok Lam Ngai, Jesse M. Tettero, Costa Bachas, Constance Baer, Marie-Christine Béné, Veit Bücklein, Anna Czyz, Barbara Denys, Richard Dillon, Michaela Feuring-Buske, Monica L. Guzman, Torsten Haferlach, Lina Han, Julia K. Herzig, Jeffrey L. Jorgensen, Wolfgang Kern, Marina Y. Konopleva, Francis Lacombe, Marta Libura, Agata Majchrzak, Luca Maurillo, Yishai Ofran, Jan Philippe, Adriana Plesa, Claude Preudhomme, Farhad Ravandi, Christophe Roumier, Marion Subklewe, Felicitas Thol, Arjan A. van de Loosdrecht, Bert A. van der Reijden, Adriano Venditti, Agnieszka Wierzbowska, Peter J. M. Valk, Brent L. Wood, Roland B. Walter, Christian Thiede, Konstanze Döhner, Gail J. Roboz, Jacqueline Cloos. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyBlood 2021; 138(26): 2753 doi: 10.1182/blood.2021013626
25
Jacqueline Cloos, Michael Heuser. Measurable Residual Disease in AMLClinical Lymphoma Myeloma and Leukemia 2021; 21: S116 doi: 10.1016/S2152-2650(21)01233-7
26
Romain Vazquez, Claire Breal, Loria Zalmai, Chloe Friedrich, Carole Almire, Adrien Contejean, Sylvain Barreau, Eric Grignano, Lise Willems, Benedicte Deau-Fischer, Patricia Franchi, Marguerite Vignon, Justine Decroocq, Rudy Birsen, Lauriane Goldwirt, Sophie Kaltenbach, Lucile Couronne, Michaela Fontenay, Olivier Kosmider, Didier Bouscary, Nicolas Chapuis. Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesisBlood Cancer Journal 2021; 11(3) doi: 10.1038/s41408-021-00448-w
27
28
Mark S. Williams, Naseer J. Basma, Fabio M. R. Amaral, Daniel H. Wiseman, Tim C. P. Somervaille. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activityBMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08839-9